<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    9722128
   </pmid>
   <datecreated>
    <year>
     1998
    </year>
    <month>
     11
    </month>
    <day>
     06
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1998
    </year>
    <month>
     11
    </month>
    <day>
     06
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0020-7292
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       62
      </volume>
      <issue>
       1
      </issue>
      <pubdate>
       <year>
        1998
       </year>
       <month>
        Jul
       </month>
      </pubdate>
     </journalissue>
     <title>
      International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
     </title>
     <isoabbreviation>
      Int J Gynaecol Obstet
     </isoabbreviation>
    </journal>
    <articletitle>
     A double-blind trial of four medications to treat severe premenstrual syndrome.
    </articletitle>
    <pagination>
     <medlinepgn>
      63-7
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To determine the efficacy of fluoxetine (10 mg), alprazolam, propanolol and pyridoxine in the treatment of severe premenstrual syndrome (PMS).
     </abstracttext>
     <abstracttext label="METHOD" nlmcategory="METHODS">
      One-hundred and twenty women were divided into four groups of 30 patients. Patients were submitted to a randomized, double-blind, placebo-controlled treatment and were given 3 months of placebo and 3 months of active drug. The active drug was pyridoxine (300 mg/day) in group 1; alprazolam (0.75 mg/day) in group 2; fluoxetine (10 mg/day) in group 3; and propanolol (20 mg/day and 40 mg during the menstrual period) in group 4.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Fluoxetine in 10-mg doses obtained a mean reduction of 65.4% in symptoms, followed by propanolol (58.7%), alprazolam (55.6%), pyridoxine (45.3%) and placebo (39.4-46.1%).
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Fluoxetine in 10-mg doses presented the best results for treating premenstrual syndrome.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Gynecology and Obstetrics, University of SÃ£o Paulo, Brazil.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Diegoli
      </lastname>
      <forename>
       M S
      </forename>
      <initials>
       MS
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       da Fonseca
      </lastname>
      <forename>
       A M
      </forename>
      <initials>
       AM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Diegoli
      </lastname>
      <forename>
       C A
      </forename>
      <initials>
       CA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Pinotti
      </lastname>
      <forename>
       J A
      </forename>
      <initials>
       JA
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     IRELAND
    </country>
    <medlineta>
     Int J Gynaecol Obstet
    </medlineta>
    <nlmuniqueid>
     0210174
    </nlmuniqueid>
    <issnlinking>
     0020-7292
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anti-Anxiety Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Serotonin Uptake Inhibitors
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      28981-97-7
     </registrynumber>
     <nameofsubstance>
      Alprazolam
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      54910-89-3
     </registrynumber>
     <nameofsubstance>
      Fluoxetine
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      65-23-6
     </registrynumber>
     <nameofsubstance>
      Pyridoxine
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Alprazolam
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anti-Anxiety Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Fluoxetine
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Premenstrual Syndrome
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pyridoxine
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Serotonin Uptake Inhibitors
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1998
     </year>
     <month>
      8
     </month>
     <day>
      29
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1998
     </year>
     <month>
      8
     </month>
     <day>
      29
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1998
     </year>
     <month>
      8
     </month>
     <day>
      29
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     9722128
    </articleid>
    <articleid idtype="pii">
     S0020729298000356
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

